- Determine the response rate and duration of response in patients treated with this
regimen.

- Determine the response rate and response rate improvement after best response to prior
salvage therapy in patients treated with this regimen.

- Determine the time to progression in patients treated with this regimen.

- Determine the safety of this regimen in these patients.

OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups according to
timing of disease progression while enrolled on protocol FAV-ID-06 (disease progression
after prior rituximab AND never randomized vs disease progression after randomization to
placebo arm).

Patients receive autologous immunoglobulin idiotype-KLH vaccine subcutaneously (SC) on day
1. Patients also receive sargramostim (GM-CSF) SC on days 1-4. Treatment repeats monthly for
6 months in the absence of disease progression or unacceptable toxicity. Patients with
stable or responding disease may receive additional treatment as above every 2 months for 1
year (6 treatments) and every 3 months until disease progression.

After completion of study treatment, patients are followed for 30 days or until the start of
subsequent treatment.

PROJECTED ACCRUAL: Approximately 238 patients (67 in group I and 171 in group II) will be
accrued for this study.

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.